Last reviewed · How we verify
Fluoropyrimidine-based Chemotherapy
Fluoropyrimidine-based chemotherapy inhibits thymidylate synthase and incorporates into DNA/RNA to disrupt cancer cell replication and survival.
Fluoropyrimidine-based chemotherapy inhibits thymidylate synthase and incorporates into DNA/RNA to disrupt cancer cell replication and survival. Used for Colorectal cancer, Gastric cancer, Breast cancer.
At a glance
| Generic name | Fluoropyrimidine-based Chemotherapy |
|---|---|
| Sponsor | Hoffmann-La Roche |
| Drug class | Antimetabolite chemotherapy |
| Target | Thymidylate synthase; DNA/RNA incorporation |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Fluoropyrimidines (such as 5-fluorouracil and its derivatives) are antimetabolites that interfere with nucleotide synthesis by inhibiting thymidylate synthase, a key enzyme in DNA synthesis. They also become incorporated into both DNA and RNA, causing direct cytotoxic damage and triggering apoptosis in rapidly dividing cancer cells. These agents are broadly used across multiple solid tumors and hematologic malignancies.
Approved indications
- Colorectal cancer
- Gastric cancer
- Breast cancer
- Pancreatic cancer
- Head and neck cancer
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia)
- Mucositis / stomatitis
- Diarrhea
- Nausea and vomiting
- Hand-foot syndrome
- Fatigue
Key clinical trials
- Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases (PHASE2, PHASE3)
- Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant (PHASE4)
- Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer (PHASE3)
- A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer) (PHASE2)
- Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis (PHASE1, PHASE2)
- Real-WorlD ZolbetUximab in Patients With HER-2 Negative and CLaudin 18.2 PosItive MetastatiC AdEnocarcinoma
- A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)
- VASCular Impact of Angiogenic Treatment in Patients With Advanced Colorectal Cancer (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fluoropyrimidine-based Chemotherapy CI brief — competitive landscape report
- Fluoropyrimidine-based Chemotherapy updates RSS · CI watch RSS
- Hoffmann-La Roche portfolio CI